Cargando…

A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need

Quantitative systems pharmacology (QSP) is a rapidly emerging discipline with application across a spectrum of challenges facing the pharmaceutical industry, including mechanistically informed prioritization of target pathways and combinations in discovery, target population, and dose expansion deci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ermakov, Sergey, Schmidt, Brian J., Musante, Cynthia J., Thalhauser, Craig J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	White Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389347/ https://www.ncbi.nlm.nih.gov/pubmed/30417600 http://dx.doi.org/10.1002/psp4.12373

Ejemplares similares

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network
por: Cucurull‐Sanchez, Lourdes, et al.
Publicado: (2019)

Population Equation: Balancing What We Need With What We Have
por: Dahl, Richard
Publicado: (2005)

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities
por: Bradshaw, Erica L., et al.
Publicado: (2019)

Neurophysiology of the Developing Cerebral Cortex: What We Have Learned and What We Need to Know
por: Luhmann, Heiko J.
Publicado: (2022)

Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need
por: Liou, Geou-Yarh, et al.
Publicado: (2023)

When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?
por: Simon, Gregory E., et al.
Publicado: (2021)

When Can We Trust Real‐World Data To Evaluate New Medical Treatments?
por: Simon, Gregory E., et al.
Publicado: (2021)

Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
por: Geerts, Hugo, et al.
Publicado: (2019)

Drugs for malaria elimination: what do we have now and what do we need?
por: Shanks, Dennis
Publicado: (2014)

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development
por: Delire, Bénédicte, et al.
Publicado: (2015)

First-Episode Psychosis care in Central Europe: What we have learned and what we still need to do
por: Réthelyi, J.
Publicado: (2022)

PTH Assays: Understanding What We Have and Forecasting What We Will Have
por: Vieira, Jose Gilberto H.
Publicado: (2012)

What have we learned and what do we still need to learn about nPDF?
por: Paakkinen, Petja
Publicado: (2021)

Paediatric schistosomiasis: What we know and what we need to know
por: Osakunor, Derick N. M., et al.
Publicado: (2018)

Conceptualizing a Genomics Software Institute (GSI)
por: Gilbert, Jack A., et al.
Publicado: (2012)

Exercise and Alcohol Consumption: What We Know, What We Need to Know, and Why it is Important
por: Leasure, J. Leigh, et al.
Publicado: (2015)

Neutrinos, what we have learned about them and what we have learned using them
por: Steinberger, J
Publicado: (2013)

Asthma in the elderly: what we know and what we have yet to know
por: Yáñez, Anahí, et al.
Publicado: (2014)

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need
por: Bidell, Monique R., et al.
Publicado: (2016)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Artificial Intelligence in Urooncology: What We Have and What We Expect
por: Froń, Anita, et al.
Publicado: (2023)

What have we learned on mesons?
por: Moebes, J P
Publicado: (1972)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

Epigenetics in Schistosomes: What We Know and What We Need Know
por: Liu, Weiwei
Publicado: (2016)

Portion Size: What We Know and What We Need to Know
por: Benton, David
Publicado: (2015)

Metabolic syndrome: what we know and what we need to know
por: Soares, Raquel
Publicado: (2020)

COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
por: Dhawan, Rahul, et al.
Publicado: (2020)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

Hallmarks of neurodegenerative disease: A systems pharmacology perspective
por: Bloomingdale, Peter, et al.
Publicado: (2022)

Psychological Interventions for Dementia Caregivers: What We Have Achieved, What We Have Learned
por: Cheng, Sheung-Tak, et al.
Publicado: (2019)

Lipoabdominoplasty: What We Have Implemented and What We Have Modified over 26 Years
por: Cárdenas-Camarena, Lázaro, et al.
Publicado: (2023)

Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know
por: Bogers, Sophie Helen
Publicado: (2018)

Membrane fission by dynamin: what we know and what we need to know
por: Antonny, Bruno, et al.
Publicado: (2016)

Erratum: asthma in the elderly: what we know and what we have yet to know
por: Yáñez, Anahí, et al.
Publicado: (2014)

Augmented Renal Clearance: What Have We Known and What Will We Do?
por: Luo, Yifan, et al.
Publicado: (2021)

The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future
por: Kuck, Karl‐Heinz, et al.
Publicado: (2018)

What We Most Need
por: De Camp, G. W.
Publicado: (1866)

In and Beyond COVID-19: US Academic Pharmaceutical Science and Engineering Community Must Engage to Meet Critical National Needs
por: Gurvich, Vadim J., et al.
Publicado: (2020)

Pregnant adolescents living with HIV: what we know, what we need to know, where we need to go
por: Callahan, Tegan, et al.
Publicado: (2017)

Nephrotoxicity testing in vitro--what we know and what we need to know.
por: Pfaller, W, et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_v2ggt2gm0c3igunnrcufcbrhfa